Comparative Pharmacology
Head-to-head clinical analysis: SYNTHROID versus TRIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNTHROID versus TRIOSTAT.
SYNTHROID vs TRIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic levothyroxine is a replacement for endogenous thyroid hormone. It binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.
TRIOSTAT (liothyronine sodium) is a synthetic form of the thyroid hormone triiodothyronine (T3). It binds to thyroid hormone receptors in the nucleus, altering gene expression and increasing cellular metabolism, oxygen consumption, and heat production.
Initial adult dose 1.6 mcg/kg orally once daily, adjusted by 12.5-25 mcg increments every 6-8 weeks based on TSH levels. Maintenance dose typically 100-125 mcg/day.
Adult: 5 mcg/kg IV every 8 hours. Adjust based on clinical response.
None Documented
None Documented
Levothyroxine (T4) terminal elimination half-life: 6-7 days in euthyroid patients; shortened to 3-4 days in hyperthyroidism and prolonged to 9-10 days in hypothyroidism; clinical context: supports once-daily dosing with steady-state reached after 6-8 weeks.
2.5 days (terminal); shortened in hyperthyroidism, prolonged in hypothyroidism
Renal: ~20-40% of T4 and T3 metabolites excreted in urine as glucuronide and sulfate conjugates; fecal: ~40-60% as unchanged drug and conjugates via biliary elimination; minor amounts in bile and feces as deiodinated products.
Renal (40% unchanged, 20% as liothyronine conjugates); fecal (35%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone